VIVES is a multi-sector fund that invests in projects with a positive societal impact
Generare is unlocking nature’s untapped potential, turning the complexity of microbial DNA into a scalable platform that can transform drug discovery.
By combining advanced biotechnology with data...
The Akkermansia company is the first co-spin-off resulting from joint research conducted at two European universities, the Catholic University of Louvain (BE) and the University of Wageningen (NL). It...
The result of more than 15 years of research in the university laboratories of UCLouvain and multiple collaborations (ELEN department, ICTEAM), the VOCSens spin-off is developing a new concept of...
Pierre Drion, business angel:
"For almost 20 years I have been passionate about what is called BioTech. This led me to invest in several companies and mainly university spin-offs. In this context, I...
Pierre Blondeau, CEO Upstreem:
"We have been working since 2017 with VIVES II, which has joined us since the beginning of our adventure. VIVES II team has an in-depth understanding of all aspects of...
Georges Caron, past CEO Keemotion:
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with the...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to